Long Term Immune Response Produced by the SputnikV Vaccine

International Journal of Molecular Sciences

Manoj Baranwal¹  Neha Kaushal¹  Richard A. Urbanowicz²  Ilsiyar M. Khaertynova³  Ekaterina Martynova⁴  Emmanuel Kabwe⁴  Maria Markelova⁴  Shaimaa Hamza⁴  Albert A. Rizvanov⁴  Svetlana F. Khaiboullina⁴  Ekaterina E. Garanina⁴  Venera Shakirova⁵ 

[1] Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala 147004, India;Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L3 5RF, UK;Department of Infectious Diseases, Kazan State Medical Academy, 420012 Kazan, Russia;IFMIB, Kazan Federal University, 420008 Kazan, Russia;Kazan State Medical Academy, 420012 Kazan, Russia;

关键词: SARS-CoV-2;    SputnikV;    Spike protein;    humoral immune response;    cellular immunity;   

DOI  :  10.3390/ijms222011211

来源: DOAJ

【 摘 要 】

SputnikV is a vaccine against SARS-CoV-2 developed by the Gamaleya National Research Centre for Epidemiology and Microbiology. The vaccine has been shown to induce both humoral and cellular immune responses, yet the mechanisms remain largely unknown. Forty SputnikV vaccinated individuals were included in this study which aimed to demonstrate the location of immunogenic domains of the SARS-CoV-2 S protein using an overlapping peptide library. Additionally, cytokines in the serum of vaccinated and convalescent COVID-19 patients were analyzed. We have found antibodies from both vaccinated and convalescent sera bind to immunogenic regions located in multiple domains of SARS-CoV-2 S protein, including Receptor Binding Domain (RBD), N-terminal Domain (NTD), Fusion Protein (FP) and Heptad Repeats (HRs). Interestingly, many peptides were recognized by immunized and convalescent serum antibodies and correspond to conserved regions in circulating variants of SARS-CoV-2. This breadth of reactivity was still evident 90 days after the first dose of the vaccine, showing that the vaccine has induced a prolonged response. As evidenced by the activation of T cells, cellular immunity strongly suggests the high potency of the SputnikV vaccine against SARS-CoV-2 infection.

【 授权许可】

Unknown